Polycythemia Vera With High Serum Erythropoietin Level: A Case Report and Literature Review

Polycythemia vera (PV) is a primary acquired marrow condition that causes erythrocytosis. It may present with erythromelalgia, pruritus, splenomegaly, and thrombotic events. Secondary causes of polycythemia should be ruled out before labeling a patient as having PV. Serum erythropoietin (EPO) level helps distinguish primary and secondary polycythemia, but it should be aided by further testing such as the JAK-2 gene mutation test. We present a case of a previously healthy 47-year-old female who came to the hospital with a headache and transient left-sided body weakness. She had no similar episodes in the past. Her initial workup showed a high hemoglobin and a high hematocrit level. A plan computed tomography (CT) scan of the head showed evidence of a thalamo-capsular infarct. The serum EPO level was elevated, and a bone marrow biopsy returned positive for JAK-2 mutation indicating the diagnosis of polycythemia vera despite the high EPO level. The World Health Organization (WHO) consensus criteria for diagnosing PV demand the presence of two major criteria and one minor criterion or the presence of the first major criterion and two minor criteria. Decreased EPO is considered a minor WHO criterion for PV diagnosis. A low EPO is also used to discriminate PV from secondary thrombocytosis, as it might be low, as expected, or elevated. Phlebotomy primarily treats PV with low risk with a target hematocrit of less than 45%. PV patients with high risk can benefit from low-dose aspirin. Anticoagulation may be added for patients with thromboembolism. Patients with polycythemia vera can present with a high or low serum EPO level. Further diagnostic tests are usually required to confirm the final diagnosis.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2024-09-17
DOI
https://doi.org/10.7759/cureus.69578
Citations
1
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.44
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Polycythemia Vera With High Serum Erythropoietin Level: A Case Report and Literature Review

Khalid Albsheer, Ahmed Alsayed, Muzamil Musa, Abdalla Fadul et al.
1 citations
Cureus
Myeloproliferative Neoplasms: Diagnosis and Treatment
0.44
article

Polycythemia Vera With High Serum Erythropoietin Level: A Case Report and Literature Review

Khalid Albsheer, Ahmed Alsayed, Muzamil Musa, Abdalla Fadul, Motaz Almahmood, Elmustafa Abdalla, Amjad M Salman
article en
1 citations

Abstract

Polycythemia vera (PV) is a primary acquired marrow condition that causes erythrocytosis. It may present with erythromelalgia, pruritus, splenomegaly, and thrombotic events. Secondary causes of polycythemia should be ruled out before labeling a patient as having PV. Serum erythropoietin (EPO) level helps distinguish primary and secondary polycythemia, but it should be aided by further testing such as the JAK-2 gene mutation test. We present a case of a previously healthy 47-year-old female who came to the hospital with a headache and transient left-sided body weakness. She had no similar episodes in the past. Her initial workup showed a high hemoglobin and a high hematocrit level. A plan computed tomography (CT) scan of the head showed evidence of a thalamo-capsular infarct. The serum EPO level was elevated, and a bone marrow biopsy returned positive for JAK-2 mutation indicating the diagnosis of polycythemia vera despite the high EPO level. The World Health Organization (WHO) consensus criteria for diagnosing PV demand the presence of two major criteria and one minor criterion or the presence of the first major criterion and two minor criteria. Decreased EPO is considered a minor WHO criterion for PV diagnosis. A low EPO is also used to discriminate PV from secondary thrombocytosis, as it might be low, as expected, or elevated. Phlebotomy primarily treats PV with low risk with a target hematocrit of less than 45%. PV patients with high risk can benefit from low-dose aspirin. Anticoagulation may be added for patients with thromboembolism. Patients with polycythemia vera can present with a high or low serum EPO level. Further diagnostic tests are usually required to confirm the final diagnosis.

CureusVol. 16(9)
Hamad Medical Corporation (QA)
Zero hunger
Openalex Percentile: Top 33%
Myeloproliferative Neoplasms: Diagnosis and Treatment
0.44
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.